Rutinib Cream — Ruxolitinib 1.5%, 30 g

Rutinib is supplied as a homogeneous, stable cream for external topical application. Each gram of the cream contains:

• Active Ingredient: Ruxolitinib Phosphate — 15 mg (equivalent to 1.5% of active ruxolitinib free base).
• Excipient Base: Cetyl alcohol, stearyl alcohol, white soft paraffin, liquid paraffin, propylene glycol, macrogol cetostearyl ether, disodium edetate, methyl hydroxybenzoate, propyl hydroxybenzoate, and purified water (carefully adjusted to maximize skin hydration, prevent emulsion cracking, and encourage smooth barrier emolliency).

Pharmacodynamics: Ruxolitinib functions as an explicit inhibitor of the Janus kinase isoforms JAK1 and JAK2. These specific intracellular enzymes act as critical conduits translating surface signals from key pro-inflammatory cytokines (such as IL-4, IL-13, IL-22, IL-31, and IFN-γ) which orchestrate the pathogenesis of atopic dermatitis and vitiligo. By downregulating the intracellular JAK-STAT pathway within active keratinocytes and infiltrating T-cells, local ruxolitinib dampens skin cell hyperactivation, safeguards active melanocytes from cytotoxic destruction, and jumpstarts cellular repair mechanisms.

Pharmacokinetics: Upon topical administrative rubbing over affected zones, ruxolitinib permeates localized skin layers. Systemic absorption profiles are profoundly minimal. Even during expansive skin application touching up to 20% of total body surface area, circulating plasma values of ruxolitinib remain trace, settling far beneath thresholds that would trigger hematological or systemic JAK-inhibitory dynamics. The micro-fraction absorbed undergoes hepatic degradation via CYP3A4 routes and is excreted cleanly as inactive metabolites through renal and fecal paths.

Rutinib Cream 1.5% is medically indicated for external topical use in adult and adolescent patients aged 12 years and older for the treatment of:

• 🔹 Atopic Dermatitis (Eczema): Chronic management of mild-to-moderate atopic dermatitis in non-immunocompromised individuals whose condition is inadequately controlled with alternative topical prescription therapies (such as corticosteroids) or when those treatments are clinically inadvisable.
• 🔹 Vitiligo (Non-Segmental): Targeted therapy for the treatment of non-segmental vitiligo to stimulate localized repigmentation across affected facial and bodily skin areas.

Rutinib Cream 1.5% protocols must be executed under the care and periodic assessment of a registered dermatologist:

• Application Guide: For external cutaneous use only. Apply a thin, uniform layer of the cream directly to affected skin regions twice daily, spaced approximately 12 hours apart. Wash hands thoroughly following application unless the hands themselves are part of the treated area.
• Volumetric Limits: Avoid applying the cream across more than 20% of the patient's total body surface area simultaneously. Do not exceed a total volumetric consumption of 60 grams (equivalent to two 30g tubes) within any single week.
• Therapeutic Duration: For atopic dermatitis, treatment continues until complete resolution of local eczematous inflammation and pruritus. For vitiligo, successful repigmentation typically demands long-term, continuous applications ranging from 6 months up to a full year.

The application of Rutinib Cream 1.5% is contraindicated or must be heavily restricted under the following clinical profiles:

• ⛔ Hypersensitivity: Documented past history of acute hypersensitivity or localized allergic reaction to ruxolitinib or any underlying chemical emulsion components.
• ⛔ Active Cutaneous Infections: Presence of untreated bacterial, virulent viral (such as herpes simplex), or fungal skin infections inside the intended treatment fields.
• ⛔ Pregnancy and Lactation: Contraindicated during pregnancy due to potential systemic embryotoxic risks. Breastfeeding must be entirely discontinued throughout the active course of therapy.
• ⛔ Pediatric Restrictions: Clinical safety guidelines have not established appropriate use patterns for children under the age of 12 years.

Co-administration alongside external or systemic therapies requires careful clinical awareness:

• ⚠️ Concomitant Topical Agents: Avoid applying Rutinib Cream concurrently over identical skin fields with other topical JAK inhibitors, topical corticosteroids, or calcineurin inhibitors (such as tacrolimus or pimecrolimus) to prevent altered tissue absorption parameters.
• ⚠️ Strong CYP3A4 Inhibitors: Patients undergoing systematic courses of powerful oral CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) should be monitored carefully, as systemic clearance of trace absorbed ruxolitinib may be decreased, slightly rising plasma presence.

Reproductive and gestational safety directives for Rutinib Cream:

• Contraception Protocols: Female patients of childbearing potential must utilize highly effective, verified contraceptive measures during the entire treatment period and maintain them for at least 4 weeks following the definitive termination of cream use.
• Maternal Safety: If a pregnancy occurs or is suspected while utilizing the product, the medication must be halted immediately, and the supervising specialist notified.

Adverse reactions associated with Rutinib Cream 1.5% are predominantly localized to application fields:

• 🟢 Localized Skin Reactions (Most Common): Transient mild stinging, application-site burning, erythema (redness), or localized tingling within the initial minutes post-application (typically subsides as skin tolerance adapts).
• 🟡 Dermatological Changes: Development of localized folliculitis (inflammation of hair follicles) or mild acneiform eruptions inside active application boundaries.
• 🟠 Systemic Sensitivities: Minor instances of nasopharyngitis (stuffy nose, throat irritation) may occur in highly susceptible individuals due to minor baseline systemic exposure.

Toxicity following localized over-application of external Rutinib cream is exceptionally rare:

• Symptoms: Accidental oral ingestion of the tube contents or extreme application over massive broken skin fields may yield systemic JAK inhibition signs (including mild transient myelosuppression, dizziness, or headache).
• Management: In case of accidental oral ingestion, initiate immediate gastric clearance protocols and administer activated charcoal. For massive cutaneous over-application, wash away excess cream layers. Provide symptomatic and supportive management.

Storage environments required to protect the chemical integrity of the active formulation:

• 🌡️ Temperature: Keep stored within its original protective cardboard packaging at a steady room temperature not exceeding 30 °C. Do not freeze the cream.
• 👶 Safety Precautions: Ensure the tube is tightly sealed after every application and stored far out of the line of sight and reach of children.
• ⏳ Shelf Life: 2 years. Once the inner aluminum seal of the tube is breached, it is highly recommended to consume the product within 6 months. Do not use after the stamped expiration date.

Genuine Rutinib Cream 1.5% by Drug International Ltd. integrates distinct physical and interactive digital anti-counterfeiting elements on its packaging to verify product authenticity:

• 🛡️ Interactive Silver Scratch-Code Panel: Centered explicitly on the main front face of the retail cardboard carton, there is a dedicated security label. This label features a rectangular silver scratch-off coating. Scratching this panel away with a coin reveals a unique, randomized alphanumeric verification security code connected directly to the manufacturer's secure database.
• 🔗 Integrated QR Code Authentication: Positioned directly to the right of the scratch panel on the same security label is a high-resolution matrix QR code. Scanning this QR code using a mobile device camera automatically redirects the patient to the official online verification engine of Drug International Ltd., automatically filling in the corresponding security code for instant validation.
• 🔒 Authentic Corporate Logo Placement: On the left-hand side of the front white carton panel, the official Drug International Ltd. logo is cleanly printed (a stylized flask/droplet emblem housing the text "DRUG"). The print execution must be perfectly sharp, showing no ink bleeding, color shifts, or misalignments. The trade name "Rutinib" is displayed in large, prominent maroon-burgundy font.
• 🔍 Mass Metric Diamond & Tube Protection: On the right end of the box, a distinct purple diamond icon highlights the product's precise weight: "30 gm" (30 grams). Inside the packaging, the aluminum tube is completely sealed across its nozzle with a tamper-proof metal induction layer. This layer is punctured using the sharp spike built into the exterior crown of the screw-on plastic cap.
• 🔢 Embossed Manufacturing Stamps: The closing end-flap of the carton packaging and the crimped base-edge of the inner aluminum tube feature heavily stamped, matching production identifiers. These cleanly outline the unique Batch Number (Batch No.), Manufacturing Date (Mfg. Date), and Expiration Date (Exp. Date). The data printed across the tube and the exterior box must align flawlessly.